drugset / Trial / NCT07802626
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
Phase 3
Not yet recruiting
1084 enrolled
SWOG Cancer Research Network
AstraZeneca · collabGuardant Health, Inc. · collabSWOG Clinical Trials Partnerships, LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research is to see if adding the investigational targeted drug capivasertib to standard endocrine therapy (hormone-blocking treatment) combined with a medicine that slows cancer cell growth can improve response to treatment for patients with metastatic breast cancer that's hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
Timeline
- Start
- 2026-10-30
- Primary completion
- 2034-10-30
- Completion
- 2035-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capivasertib | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Comparator | Palbociclib | Small molecule | — | — |
| Comparator | Ribociclib | Small molecule | — | — |